Molecular abnormalities in chronic myeloid leukemia: deregulation of cell growth and apoptosis.

Chronic myeloid leukemia (CML) is a disease of the hematopoietic system, characterized by the presence of the Bcr-Abl oncoprotein. The main characteristics of this disease include adhesion independence, growth factor independence, and resistance to apoptosis. Loss or mutation of the tumor suppressor gene, p53, is one of the most frequent secondary mutations in CML blast crisis. The transition between chronic phase and blast crisis is associated with increased resistance to apoptosis correlating with poor prognosis. This review focuses on the involvement of these two oncoproteins in the development and progression of the apoptotic-resistant phenotype in CML.

[1]  M. Bernard,et al.  BCR-ABL and constitutively active erythropoietin receptor (cEpoR) activate distinct mechanisms for growth factor-independence and inhibition of apoptosis in Ba/F3 cell line , 1998, Oncogene.

[2]  A. Levine,et al.  Proteolytic Cleavage of the mdm2 Oncoprotein during Apoptosis* , 1997, The Journal of Biological Chemistry.

[3]  K. Miyazono,et al.  Apoptosis inhibitory activity of cytoplasmic p21Cip1/WAF1 in monocytic differentiation , 1999, The EMBO journal.

[4]  S. Lo,et al.  Molecular Cloning Of Human Paxillin, a Focal Adhesion Protein Phosphorylated by P210BCR/ABL(*) , 1995, The Journal of Biological Chemistry.

[5]  J. Wilson-Rawls,et al.  P210 Bcr-Abl interacts with the interleukin 3 receptor beta(c) subunit and constitutively induces its tyrosine phosphorylation. , 1996, Cancer research.

[6]  O. Witte,et al.  BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner , 1991, Cell.

[7]  K. Ichimura,et al.  Deregulation of the p 14 ARF / MDM 2 / p 53 Pathway Is a Prerequisite for Human Astrocytic Gliomas with G 1S Transition Control Gene Abnormalities 1 , 2000 .

[8]  T. Cotter,et al.  Molecular mechanisms of programmed cell death. , 1998, Advances in biochemical engineering/biotechnology.

[9]  J P Luzio,et al.  Cell surface trafficking of Fas: a rapid mechanism of p53-mediated apoptosis. , 1998, Science.

[10]  D. Haber,et al.  The WT1 gene product stabilizes p53 and inhibits p53-mediated apoptosis. , 1995, Genes & development.

[11]  P. Laneuville,et al.  bcr/abl expression in 32D cl3(G) cells inhibits apoptosis induced by protein tyrosine kinase inhibitors. , 1994, Cancer research.

[12]  S. McKenna,et al.  Functional aspects of apoptosis in hematopoiesis and consequences of failure. , 1997, Advances in cancer research.

[13]  C. Sawyers,et al.  Signal transduction by wild-type and leukemogenic Abl proteins. , 1997, Biochimica et biophysica acta.

[14]  B. Druker,et al.  The SH2 domain of ABL is not required for factor-independent growth induced by BCR-ABL in a murine myeloid cell line. , 1995, Leukemia.

[15]  R. Jove,et al.  Constitutive activation of the JAK2/STAT5 signal transduction pathway correlates with growth factor independence of megakaryocytic leukemic cell lines. , 1999, Blood.

[16]  S. Ferrari,et al.  Wt-p53 action in human leukaemia cell lines corresponding to different stages of differentiation. , 1998, British Journal of Cancer.

[17]  T Pawson,et al.  Bcr‐Abl oncoproteins bind directly to activators of the Ras signalling pathway. , 1994, The EMBO journal.

[18]  M. Shibuya,et al.  A novel pathway from phosphorylation of tyrosine residues 239/240 of Shc, contributing to suppress apoptosis by IL‐3. , 1996, The EMBO journal.

[19]  C. Sawyers,et al.  Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene , 1995, The Journal of experimental medicine.

[20]  J. Wang,et al.  Deletion of an N‐terminal regulatory domain of the c‐abl tyrosine kinase activates its oncogenic potential. , 1989, The EMBO journal.

[21]  J. Nevins,et al.  E2F1-specific induction of apoptosis and p53 accumulation, which is blocked by Mdm2. , 1998, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[22]  T. Gonda,et al.  Long-term exposure to retrovirally expressed granulocyte-colony-stimulating factor induces a nonneoplastic granulocytic and progenitor cell hyperplasia without tissue damage in mice. , 1989, The Journal of clinical investigation.

[23]  John Calvin Reed,et al.  Tumor suppressor p53 is a direct transcriptional activator of the human bax gene , 1995, Cell.

[24]  M. Schwartz,et al.  Integrin regulation of c-Abl tyrosine kinase activity and cytoplasmic-nuclear transport. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[25]  R. A. Etten.  Cycling, stressed-out and nervous: cellular functions of c-Abl , 1999 .

[26]  W. El-Deiry,et al.  Regulation of p53 downstream genes. , 1998, Seminars in cancer biology.

[27]  J. Wang,et al.  Reduction in protein tyrosine phosphorylation during differentiation of human leukemia cell line K-562. , 1987, Cancer research.

[28]  C. Verfaillie,et al.  Direct contact between human primitive hematopoietic progenitors and bone marrow stroma is not required for long-term in vitro hematopoiesis. , 1992, Blood.

[29]  M. Bar‐eli,et al.  The spectrum of molecular alterations in the evolution of chronic myelocytic leukemia. , 1991, The Journal of clinical investigation.

[30]  James D. Griffin,et al.  p130CAS Forms a Signaling Complex with the Adapter Protein CRKL in Hematopoietic Cells Transformed by the BCR/ABL Oncogene* , 1996, The Journal of Biological Chemistry.

[31]  O. Witte,et al.  Initiation of deregulated growth of multipotent progenitor cells by bcr-abl in vitro. , 1992, Science.

[32]  Phang-lang Chen,et al.  Phosphorylation of the retinoblastoma gene product is modulated during the cell cycle and cellular differentiation , 1989, Cell.

[33]  L. Neckers,et al.  Stabilization of wild-type p53 by hypoxia-inducible factor 1α , 1998, Nature.

[34]  A. Levine,et al.  P19(ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[35]  D. Lane,et al.  p53, guardian of the genome , 1992, Nature.

[36]  T. Mahdi,et al.  Rescue of K562 cells from MDM2‐modulated p53‐dependent apoptosis by growth factor‐induced differentiation , 1998, Biology of the cell.

[37]  A. Levine,et al.  Regulation of the p53 protein by the MDM2 oncoprotein--thirty-eighth G.H.A. Clowes Memorial Award Lecture. , 1999, Cancer research.

[38]  W. El-Deiry,et al.  BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: a mechanism of resistance to multiple anticancer agents. , 1995, Blood.

[39]  J. Brugge,et al.  Integrins and signal transduction pathways: the road taken. , 1995, Science.

[40]  P. Rothman,et al.  Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients. , 1997, Journal of immunology.

[41]  Donald Metcalf,et al.  BCR – ABL activates pathways mediating cytokine independence and protection against apoptosis in murine hematopoietic cells in a dose-dependent manner , 1998, Oncogene.

[42]  B. Calabretta,et al.  Transformation of hematopoietic cells by BCR/ABL requires activation of a PI‐3k/Akt‐dependent pathway , 1997, The EMBO journal.

[43]  O. Witte,et al.  Cell lines and clinical isolates derived from Ph1-positive chronic myelogenous leukemia patients express c-abl proteins with a common structural alteration. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[44]  C. Peters,et al.  Potential role for Cathepsin D in p53-dependent tumor suppression and chemosensitivity , 1998, Oncogene.

[45]  L. Gaboury,et al.  Unregulated proliferation of primitive chronic myeloid leukemia progenitors in the presence of normal marrow adherent cells. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[46]  J L Cleveland,et al.  Cytokine rescue of p53-dependent apoptosis and cell cycle arrest is mediated by distinct Jak kinase signaling pathways. , 1998, Genes & development.

[47]  A. Sacchi,et al.  The insulin-like growth factor I receptor as a physiologically relevant target of p53 in apoptosis caused by interleukin-3 withdrawal , 1997, Molecular and cellular biology.

[48]  J. Rowley.  A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia identified by Quinacrine Fluorescence and Giemsa Staining , 1973, Nature.

[49]  S. Velasco-Miguel,et al.  Induction of the growth inhibitor IGF-binding protein 3 by p53 , 1995, Nature.

[50]  J. Darnell,et al.  Interferon-dependent tyrosine phosphorylation of a latent cytoplasmic transcription factor. , 1992, Science.

[51]  C. Willman,et al.  Activation of the interleukin-3 gene by chromosome translocation in acute lymphocytic leukemia with eosinophilia [see comments] , 1990 .

[52]  A. Keating.  Ph positive CML cell lines. , 1987, Bailliere's clinical haematology.

[53]  G. Daley,et al.  Secondary mutation maintains the transformed state in BaF3 cells with inducible BCR/ABL expression. , 1998, Blood.

[54]  M. Pincus,et al.  MEKK1/JNK signaling stabilizes and activates p53. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[55]  R. Lang,et al.  Nonneoplastic hematopoietic myeloproliferative syndrome induced by dysregulated multi-CSF (IL-3) expression. , 1989, Blood.

[56]  P. Chumakov,et al.  Distinct effects of various p53 mutants on differentiation and viability of human K562 leukemia cells. , 1997, Oncology research.

[57]  R. Jove,et al.  STAT proteins as novel targets for cancer therapy. Signal transducer an activator of transcription. , 1999, Current opinion in oncology.

[58]  D. Green,et al.  Bcl-2-independent Bcr–Abl-mediated resistance to apoptosis: protection is correlated with up regulation of Bcl-xL , 1998, Oncogene.

[59]  I. Hariharan,et al.  bcr-abl oncogene renders myeloid cell line factor independent: potential autocrine mechanism in chronic myeloid leukemia. , 1988, Oncogene research.

[60]  C. Prives,et al.  p53: puzzle and paradigm. , 1996, Genes & development.

[61]  I. Sánchez-García,et al.  Tumorigenic activity of the BCR-ABL oncogenes is mediated by BCL2. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[62]  G. Daley,et al.  Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. , 1990, Science.

[63]  M. Shibuya,et al.  Deletion of the ABL SH3 domain reactivates de‐oligomerized BCR‐ABL for growth factor independence , 1996, FEBS letters.

[64]  Xin Lu,et al.  RB regulates the stability and the apoptotic function of p53 via MDM2. , 1999, Molecular cell.

[65]  A. Fields,et al.  Protein Kinase Cι Activity Is Necessary for Bcr-Abl-mediated Resistance to Drug-induced Apoptosis* , 1999, Journal of Biological Chemistry.

[66]  M. Oren,et al.  Relationship of sequence-specific transactivation and p53-regulated apoptosis in interleukin 3-dependent hematopoietic cells. , 1996, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[67]  M. Collins,et al.  Interleukin 3 protects murine bone marrow cells from apoptosis induced by DNA damaging agents , 1992, The Journal of experimental medicine.

[68]  S. Ghaffari,et al.  Growth factor independence and BCR/ABL transformation: promise and pitfalls of murine model systems and assays , 1999, Leukemia.

[69]  L. Donehower,et al.  Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours , 1992, Nature.

[70]  I. Hariharan,et al.  A lethal myeloproliferative syndrome in mice transplanted with bone marrow cells infected with a retrovirus expressing granulocyte‐macrophage colony stimulating factor. , 1989, The EMBO journal.

[71]  D. Lane,et al.  Cancer. p53, guardian of the genome. , 1992, Nature.

[72]  B. Payrastre,et al.  Integrin-dependent translocation of phosphoinositide 3-kinase to the cytoskeleton of thrombin-activated platelets involves specific interactions of p85 alpha with actin filaments and focal adhesion kinase , 1995, The Journal of cell biology.

[73]  M. Montenarh,et al.  Regulation of CAK kinase activity by p53 , 1998, Oncogene.

[74]  R. Kurzrock,et al.  Effect of differentiation‐inducing agents on oncogene expression in a chronic myelogenous leukemia cell line , 1988, Cancer.

[75]  G. Daley,et al.  Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[76]  A. Whetton,et al.  Activation of the Abelson tyrosine kinase activity is associated with suppression of apoptosis in hemopoietic cells. , 1993, Cancer research.

[77]  K. Ichimura,et al.  Deregulation of the p14ARF/MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S transition control gene abnormalities. , 2000, Cancer research.

[78]  G. Blandino,et al.  Wild-type p53 modulates apoptosis of normal, IL-3 deprived, hematopoietic cells. , 1995, Oncogene.

[79]  K. Kinzler,et al.  A model for p53-induced apoptosis , 1997, Nature.

[80]  M. Schwartz,et al.  Integrins: emerging paradigms of signal transduction. , 1995, Annual review of cell and developmental biology.

[81]  X Zhang,et al.  Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia. , 1998, Blood.

[82]  C. Peschel,et al.  Primary proliferating immature myeloid cells from CML patients are not resistant to induction of apoptosis by DNA damage and growth factor withdrawal , 1996, British journal of haematology.

[83]  J. McCubrey,et al.  Signal transduction, cell cycle regulatory, and anti-apoptotic pathways regulated by IL-3 in hematopoietic cells: possible sites for intervention with anti-neoplastic drugs , 1999, Leukemia.

[84]  R. Ren,et al.  Bcr-Abl with an SH3 Deletion Retains the Ability To Induce a Myeloproliferative Disease in Mice, yet c-Abl Activated by an SH3 Deletion Induces Only Lymphoid Malignancy , 1999, Molecular and Cellular Biology.

[85]  D. Cortez,et al.  Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis , 1995, Molecular and cellular biology.

[86]  M. Kastan,et al.  Growth factor modulation of p53-mediated growth arrest versus apoptosis. , 1995, Genes & development.

[87]  B. Druker,et al.  Use of a temperature-sensitive mutant to define the biological effects of the p210BCR-ABL tyrosine kinase on proliferation of a factor-dependent murine myeloid cell line. , 1994, Oncogene.

[88]  Lewis C Cantley,et al.  PI3K: Downstream AKTion Blocks Apoptosis , 1997, Cell.

[89]  F. Grand,et al.  Apoptosis in chronic myeloid leukaemia: normal responses by progenitor cells to growth factor deprivation, X‐irradiation and glucocorticoids , 1995, British journal of haematology.

[90]  D. G. Osmond,et al.  Upregulation of endogenous p53 and induction of in vivo apoptosis in B‐lineage lymphomas of Eμ‐myc transgenic mice by deregulated c‐myc transgene , 1997, Molecular carcinogenesis.

[91]  T. Golub,et al.  p210BCR/ABL, p190BCR/ABL, and TEL/ABL activate similar signal transduction pathways in hematopoietic cell lines. , 1996, Oncogene.

[92]  M. Collins,et al.  In bone marrow derived Baf-3 cells, inhibition of apoptosis by IL-3 is mediated by two independent pathways , 1997, Oncogene.

[93]  T. Hunter,et al.  Transcriptional control by protein phosphorylation: signal transmission from the cell surface to the nucleus , 1995, Current Biology.

[94]  K. Kinzler,et al.  14-3-3σ Is a p53-Regulated Inhibitor of G2/M Progression , 1997 .

[95]  M. Kubbutat,et al.  Keeping an old friend under control: regulation of p53 stability. , 1998, Molecular medicine today.

[96]  J. Dick,et al.  Expression of bcr-abl abrogates factor-dependent growth of human hematopoietic M07E cells by an autocrine mechanism. , 1994, Blood.

[97]  S. Anderson,et al.  The BCR-ABL oncogene requires both kinase activity and src-homology 2 domain to induce cytokine secretion. , 1996, Blood.

[98]  B. Calabretta,et al.  Blastic transformation of p53-deficient bone marrow cells by p210bcr/abl tyrosine kinase. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[99]  M. Greaves,et al.  ts BCR-ABL kinase activation confers increased resistance to genotoxic damage via cell cycle block. , 1996, Oncogene.

[100]  A. Gotoh,et al.  Tyrosine phosphorylation and activation of focal adhesion kinase (p125FAK) by BCR-ABL oncoprotein. , 1995, Experimental hematology.

[101]  S. Benchimol,et al.  Cytokines inhibit p53-mediated apoptosis but not p53-mediated G1 arrest , 1995, Molecular and cellular biology.

[102]  C. Chresta,et al.  Characterization of drug resistance mediated via the suppression of apoptosis by Abelson protein tyrosine kinase. , 1995, Molecular pharmacology.

[103]  C. Willman,et al.  Activation of the interleukin-3 gene by chromosome translocation in acute lymphocytic leukemia with eosinophilia. , 1990, Blood.

[104]  G. Daley,et al.  Overlapping cDNA clones define the complete coding region for the P210c-abl gene product associated with chronic myelogenous leukemia cells containing the Philadelphia chromosome. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[105]  Eaves Ac,et al.  Maintenance and proliferation control of primitive hemopoietic progenitors in long-term cultures of human marrow cells. , 1988 .

[106]  R. Kurzrock,et al.  Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation. , 1993, The Journal of clinical investigation.

[107]  H. Kantarjian,et al.  Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients. , 1987, The American journal of medicine.

[108]  C. Sherr,et al.  Tumor surveillance via the ARF-p53 pathway. , 1998, Genes & development.

[109]  M. Serrano,et al.  p19ARF links the tumour suppressor p53 to Ras , 1998, Nature.

[110]  H. Boswell,et al.  BCR/ABL confers growth factor independence upon a murine myeloid cell line. , 1992, Leukemia.

[111]  S. Lo,et al.  Increased tyrosine phosphorylation of focal adhesion proteins in myeloid cell lines expressing p210BCR/ABL. , 1995, Oncogene.

[112]  G. Zon,et al.  Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells. , 1995, Blood.

[113]  J. Griffin,et al.  Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl , 1996, The Journal of experimental medicine.

[114]  A. Fornace,et al.  p53-dependent and -independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor alpha. , 1998, Cancer research.

[115]  R. Weichselbaum,et al.  Determination of cell fate by c-Abl activation in the response to DNA damage , 1998, Oncogene.

[116]  A. Rebollo,et al.  Novel aspects of Ras proteins biology: regulation and implications , 1999, Cell Death and Differentiation.

[117]  G. Hannon,et al.  The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA , 1994, Nature.

[118]  D. Cortez,et al.  The Bcr-Abl tyrosine kinase activates mitogenic signaling pathways and stimulates G1-to-S phase transition in hematopoietic cells , 1997, Oncogene.

[119]  C. Sawyers,et al.  The nuclear tyrosine kinase c-abl negatively regulates cell growth , 1994, Cell.

[120]  L. Varticovski,et al.  BCR/abl leads to the constitutive activation of Stat proteins, and shares an epitope with tyrosine phosphorylated Stats. , 1996, Leukemia.

[121]  E. May,et al.  Human and Mouse Fas (APO-1/CD95) Death Receptor Genes Each Contain a p53-responsive Element That Is Activated by p53 Mutants Unable to Induce Apoptosis* , 2000, The Journal of Biological Chemistry.